Pretreatment plasma -dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer

Abstract

Objective To evaluate the prognostic accuracy of d -dimer levels for advanced non-small-cell lung cancer (NSCLC). Methods This retrospective cohort study included 651 patients initially diagnosed with advanced NSCLC. Patients with d -dimer levels ≥0.5 mg/L were included in the high d -dimer group, whereas patients with lower levels were included in the normal group. Cumulative survival was estimated using Kaplan–Meier curves and compared using the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. Results The median plasma d -dimer level in the study cohort was 0.61 ± 0.49 mg/L. d -dimer levels were elevated in 60.98% of patients, and 80.1% of such patients had adenocarcinoma. Univariate and multivariate analyses identified d -dimer content as an independent factor for the prognosis of NSCLC (hazard ratio [HR] = 1.54, 95% confidence interval [CI] = 1.19–1.98). Kaplan–Meier analysis revealed that high plasma d -dimer levels were associated with shorter overall survival (HR = 1.48, 95% CI = 1.19–1.84). In addition, the receipt of 2 lines. Conclusion The present results imply that pretreatment plasma d -dimer levels could represent a prognostic factor for advanced NSCLC.